Integrated DNA Technologies Executive and Leadership Team

Alfonso Avila, the Group Chief Executive Officer at Integrated DNA Technologies, directs the overarching corporate strategy and global operations. Avila guides the company's expansion within the academic research, biotechnology, clinical diagnostics, and pharmaceutical development sectors. This leadership role involves setting long-term objectives and ensuring alignment across all business units to drive market leadership. Avila's strategic vision focuses on enhancing Integrated DNA Technologies' position as a premier supplier of custom nucleic acids. By fostering cross-functional collaboration, Avila ensures operational efficiency and the successful execution of company-wide initiatives. The Chief Executive Officer's mandate includes cultivating a culture of innovation and accountability, directly impacting the company's sustained growth and its contribution to advancements in life sciences. Alfonso Avila's executive oversight ensures the company consistently meets the evolving needs of its diverse client base.

Alan M, the Chief Financial Officer at Integrated DNA Technologies, manages the company's financial health and strategic fiscal planning. M oversees all financial operations, including budgeting, forecasting, and capital allocation, ensuring robust financial controls and compliance. This role is critical for supporting Integrated DNA Technologies' growth initiatives across academic research, biotechnology, and clinical diagnostics. The Chief Financial Officer analyzes market trends and financial performance to identify opportunities for increased profitability and operational efficiency. M's expertise guides investment decisions and resource management, directly impacting the company's ability to fund research and development and expand its market reach. By maintaining strong financial discipline, Alan M ensures the company's long-term stability and its capacity to deliver value to stakeholders. This executive leadership underpins the company's operational and strategic objectives.

Ajay Gannerkote, the President At IDT, A Danaher Company, directs the operational execution and strategic implementation of business objectives. Gannerkote oversees the day-to-day management of Integrated DNA Technologies, ensuring seamless integration with Danaher's broader portfolio and driving performance improvements. This leadership position focuses on optimizing manufacturing processes and supply chain logistics for custom nucleic acids, serving academic research, biotechnology, and pharmaceutical development sectors. The President ensures that operational strategies align with market demands and company growth targets. Gannerkote's responsibilities include fostering a culture of continuous improvement and operational excellence across all departments. By driving efficiency and innovation in operations, Ajay Gannerkote directly contributes to Integrated DNA Technologies' market leadership and its ability to meet client needs effectively. This executive's focus ensures sustained operational success.

Chuen-Der Lien, the Chief Technology Officer at Integrated DNA Technologies, architects the company's technological roadmap and innovation pipeline. Lien oversees the development and implementation of cutting-edge technologies essential for manufacturing custom nucleic acids. This involves driving research and development efforts that enhance product quality and expand service offerings for academic research, biotechnology, and pharmaceutical development. The Chief Technology Officer ensures that Integrated DNA Technologies maintains a competitive edge through advanced scientific methodologies and robust production capabilities. Lien's responsibilities include managing intellectual property and fostering collaborations with external research institutions to accelerate technological breakthroughs. By focusing on scalable and efficient technological solutions, Chuen-Der Lien directly supports the company's mission to provide high-quality nucleic acid products. This leadership ensures the company's continued advancement in the life sciences industry.